UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 1, 2002
DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-16133 06-1245881
(State or other jurisdiction of (Commission File (IRS Employer
incorporation) Number) Identification No.)
1100 Summer Street, Stamford, Connecticut 06905
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (203) 323-8668
N/A
(Former name or former address, if changed since last report)
5. Other Events and Regulation FD Disclosure
On October 1, 2002, Delcath Systems, Inc. (the "Company") issued a press
release announcing that its board of directors approved a stock repurchase
program whereby the Company is authorized to repurchase a portion of its common
stock. The Company's press release dated October 1, 2002 is incorporated herein
by reference and filed as an exhibit hereto.
Item 7. Financial Statements and Exhibits
(a) Not applicable
(b) Not applicable
(c) Exhibits
Exhibit No. Description
99 Press Release dated October 1, 2002 of
Delcath Systems, Inc.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DELCATH SYSTEMS, INC.
By: /s/ M. S. KOLY
--------------------------------------
M. S. Koly
President and Chief Executive Officer
Date: October 2, 2002
3
EXHIBIT INDEX
Exhibit No. Description
99 Press Release dated October 1, 2002 of
Delcath Systems, Inc.
Exhibit 99
Contact:
M.S. Koly Thomas Redington
Chief Executive Officer Redington, Inc
Delcath Systems, Inc. 203/222-7399
203/323-8668 212/926-1733
www.delcath.com www.redingtoninc.com
DELCATH APPROVES STOCK REPURCHASE PROGRAM
STAMFORD, CT OCT. 1 - Delcath Systems, Inc. (Nasdaq: DCTH) today announced
that its board of directors approved a stock repurchase program whereby the
company is authorized to repurchase a portion of its common stock.
The board approved the repurchase by the company of up to 7 percent of its
outstanding common stock at such times, at such prices and on such other terms
as the president and chief executive officer approves. Under the board's
authorization, the company is not obligated to repurchase any shares. Certain of
the directors of the company have also indicated that they may purchase
additional shares for their own account. Any purchases the company or its
directors may make will depend on market conditions.
Delcath's common stock is listed on the Nasdaq Small Cap Market and the
Boston Stock Exchange under the symbols DCTH and DCT, respectively.
Delcath, a development-stage company, is in the business of developing and
marketing a proprietary drug delivery system capable of introducing, and
removing, high-dose chemotherapy agents to a diseased organ system while greatly
inhibiting their entry into the general circulatory system.
# # #
This release contains "forward-looking statements" based on current
expectations but involving known and unknown risks and uncertainties. Actual
results or achievements may be materially different from those expressed or
implied. Delcath plans and objectives are based on assumptions involving
judgments with respect to future economic, competitive and market conditions,
its ability to consummate, and the
timing of, acquisitions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are beyond its
control. Therefore, there can be no assurance than any forward-looking statement
will prove to be accurate.
10/1/02